Natco Pharma gets emergency use approval from CDSCO for Baricitinib tablets for Covid-19 treatment

03 May 2021 Evaluate

Natco Pharma has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.

Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic. The company is ready to launch the product this week, so as to make the product available to suffering patients across India.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

903.65 -29.95 (-3.21%)
08-Dec-2025 12:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.00
Dr. Reddys Lab 1270.00
Cipla 1508.15
Zydus Lifesciences 926.95
Lupin 2071.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×